





7-10 novembre 2013

NET del tratto uro-genitale




Antonio Bianchi Divisione di Endocrinologia Policlinico Universitario "Agostino Gemelli" Università Cattolica del Sacro Cuore Roma



NET of the genitourinary tract



7-10 novembre 2013





NET of the genitourinary tract



7-10 novembre 2013

Typical carcinoid

A tumour with carcinoid morphology and less than 2 mitoses per 2 mm² (10 HPF), lacking necrosis and 0.5 cm or larger

Atypical carcinoid

A tumour with carcinoid morphology with 2-10 mitoses per 2 mm² (10 HPF) OR necrosis (often punctate)

Large cell neuroendocrine carcinoma

- 1. A tumour with a neuroendocrine morphology (organoid nesting, palisading, rosettes, trabeculae)
- 2. High mitotic rate: 11 or greater per 2 mm² (10 HPF), median of 70 per 2 mm² (10 HPF)
- 3. Necrosis (often large zones)
- 4. Cytologic features of a non-small cell carcinoma (NSCLC): large cell size, low nuclear to cytoplasmic ratio, vesicular, coarse or fine chromatin, and/or frequent nucleoli. Some tumours have fine nuclear chromatin and lack nucleoli, but qualify as NSCLC because of large cell size and abundant cytoplasm.
- 5. Positive immunohistochemical staining for one or more NE markers (other than neuron specific enolase) and/or NE granules by electron microscopy.

Small cell carcinoma

Small size (generally less than the diameter of 3 small resting lymphocytes)

- 1. Scant cytoplasm
- 2. Nuclei: finely granular nuclear chromatin, absent or faint nucleoli
- 3. High mitotic rate (11 or greater per 2 mm² (10 HPF), median of 80 per 2 mm² (10 HPF)
- 4. Frequent necrosis often in large zones

Travis W.D., Brambilla E., Muller-Hermelink H.K., Harris C.C. (Eds.): World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. IARC Press: Lyon 2004.



NET of the genitourinary tract are rare!



7-10 novembre 2013

Niigata Registry (1953-2002): Analysis of 11842 Reported Cases

Table II - Organ distribution of the carcinoid group and variant group

	Carcinoid group:	Typical	Atypical	T/A	Variant group	Overall
Organ/Site	No. / %	No. / %	No. / %		No. / %	No. / %
Digestive system	6933/ 64.2	6409/ 68.0	524/ 38.1	12.2	486/ 46.8	7419/ 62.6
Extradigestive system	3871/ 35.8	3021/ 32.0	850/ 61.9	3.6	552/ 53.2	4423/ 37.4
Respiratory system	2143/ 19.8	1760/ 18.7	383/ 27.9	4.6	130/ 12.5	2273/ 19.2
Mediastinum/thymus	501/ 4.6	415/ 4.4	86/ 6.3	4.8	18/ 1.7	519/ 4.4
Breast	206/ 1.9	105/ 1.1	101/ 7.4	1.0	125/ 12.0	331/ 2.8
Ovary	352/ 3.3	336/ 3.6	16/ 1.2	21.0	1/ 0.1	353/ 3.0
Larynx	241/ 2.2	42/ 0.4	199/ 14.5	0.2	44/ 4.2	285/ 2.4
Uterine cervix	85/ 0.8	51/ 0.5	34/ 2.5	1.5	132/ 12.7	217/ 1.8
Middle ear	72/ 0.7	55/ 0.6	17/ 1.2	3.2	5/ 0.4	77/ 0.7
Kidney	60/ 0.6	57/ 0.6	3/ 0.2	19.0	14/ 1.3	74/ 0.6
Testicle	70/ 0.7	70/ 0.7	0/ 0.0		0/ 0.0	70/ 0.6
Urinary bladder	22/ 0.2	19/ 0.2	3/ 0.2	6.3	56/ 5.4	78/ 0.7
Sites unspecified**	119/ 1.1	111/ 1.2	8/ 0.6	13.9	27/ 2.6	146/ 1.2
Overall/ average	10804/100.0	9430/100.0	1374/100.0	6.9	1038/100.0	11842/100.0

* Including 106 cases in Meckel's diverticulum. ** Including 20 in the retroperitoneal region, 16 in the uterine body, 11 in the skin and 9 in the prostate. T/A: Ratio of typical & atypical carcinoids.



Renal Carcinoid



Epidemiology/etiology/histological type/clinical presentation/prognosis

- Rare; association with teratoma (18%), horseshoe kidney (14%), polycystic kidney disease (2%)
- ✓ About 100 cases described in literature (first report in 1966); no gender preference
- ✓ Mean age at diagnosis: 49 (13-79)
- Histological types: typical histologic features of carcinoids in other organs of the body.
- Presentation: incidental, no specific finding on computed tomography (CT) or magnetic resonance imaging (MRI), abdominal, back or flank pain, mass (1,5-30 cm), haematuria, anemia. Carcinoid syndrome symptoms are uncommon (<10%). Octreotide scintigraphy more useful than FDG-PET.
- ✓ The clinical outcome is difficult to predict and a significant proportion of patients with metastatic disease (50% of cases, lymphnodes, liver and bone) have a protracted clinical course.





Epidemiology/etiology/histological type/clinical presentation/prognosis

- \checkmark 1% of all epithelial renal malignancies
- ✓ Average age: 60 years, with no sex predilection.
- Histological types: nests and trabecula of poorlydifferentiated small, round to fusiform cells; <u>a concomitant</u> <u>urothelial carcinoma is common</u>
- Presentation: Abdominal pain and gross haematuria are the most frequent clinical symptoms
- The prognosis is poor and stage dependent. At least, 75% of patients die of their disease within one year regardless of treatment.

Mazzucchelli BJU Int. 2009 Jun;103(11):1464-70.Korkmaz, Critical Reviews in Oncology/Hematology 87 (2013) 256–264 ; Aung Human Pathology (2013) 44, 873–880; Jeung, Human Pathology (2011) 42, 1554–1561; Eble, Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs IARC/WHO 2004



Bladder Carcinoid



Epidemiology/Etiology/Histological type/clinical presentation/prognosis

- Rare:less than two-dozen cases of carcinoid tumours of the urinary bladder have been reported
- Elderly patients (mean age, 56 years; range, 29-75 years), with slight male predominance
- ✓ Presentation: hematuria is the most common clinical presentation, followed by irritative symptoms. <u>Association with carcinoid syndrome has not been reported</u>.
- Histologically similar to their counterparts in other organ sites, these tumours are submucosal with a predilection for the trigone and bladder neck. The tumour often presents as a polypoid lesion (3-30 mm). Coexistence of carcinoid with other urothelial neoplasia has been reported.
- ✓ Differential diagnosis: paraganglioma, urothelial carcinoma and metastastic prostatic carcinoma.
- Prognosis: more than 25% of patients with pure carcinoid will have regional lymph node or distant metastasis but majority are cured by excision.

Mazzucchelli BJU Int. 2009 Jun;103(11):1464-70.Korkmaz, Critical Reviews in Oncology/Hematology 87 (2013) 256–264 ; Aung Human Pathology (2013) 44, 873–880; Jeung, Human Pathology (2011) 42, 1554–1561; Chang, JTUA 18:154-6, 2007; Eble, Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs IARC/WHO 2004



Testicular Carcinoid



Epidemiology/Etiology/Histological type/clinical presentation

- ✓ Rare; 0.5-0.6% of all carcinoid tumors; 0.1-0.2 % of testicular neoplasm
- ✓ About 100 cases described in literature
- ✓ Mean age at diagnosis: 46 years (range 10-84)
- ✓ Histological types: pure or primary (insular and trabecular), associated with teratoma, secondary metastatic to the testis
- Presentation: incidental, testicular mass (10-95 mm) or diffuse testicular enlargement. More common in the left, infrequently metastasizes, rarely with carcinoid syndrome (1-10%)

Palla, Case Rep Oncol 2012;5:43–46; Mazzucchelli BJU Int. 2009 Jun;103(11):1464-70.Korkmaz, Critical Reviews in Oncology/Hematology 87 (2013) 256–264 ; Aung Human Pathology (2013) 44, 873–880; Jeung, Human Pathology (2011) 42, 1554–1561; Chang, JTUA 18:154-6, 2007; Eble, Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs IARC/WHO 2004



Testicular Carcinoid



Prognosis

- ✓ Correlated with tumor staging
- The critical issue in determining therapy for testicular carcinoids is the demonstration of metastatic disease.
- ✓ In localized cases (90.8% of those reported), orchiectomy is usually curative, while those who presented with metastatic disease (9.2%) had a more severe, unsuccessful clinical course with an average survival time of 2 years

Palla, Case Rep Oncol 2012;5:43–46; Mazzucchelli BJU Int. 2009 Jun;103(11):1464-70.Korkmaz, Critical Reviews in Oncology/Hematology 87 (2013) 256–264 ; Aung Human Pathology (2013) 44, 873–880; Jeung, Human Pathology (2011) 42, 1554–1561; Chang, JTUA 18:154-6, 2007; Eble, Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs IARC/WHO 2004



Ovarian Carcinoid



Epidemiology/Etiology/Histological type

- ✓ Rare; 0.5-3% of all carcinoid tumors; 0.1% of ovarian neoplasm
- ✓ About 500 cases described in literature
- ✓ Mean age at diagnosis: 55 years (range 14-83)
- ✓ histological types: insular, stromal, mucinous and trabecular; isolation or accompanied by dermoid cyst, mucinous cystic tumor or a Brenner tumor; mostly associated with teratoma



Ovarian Carcinoid



Clinical presentation


- ✓ abdominal pain; incidentally, during clinical/ radiological/hystopathological examination
- ✓ pelvic mass
- ✓ severe constipation (peptide YY)
- hirsutism (peptide YY,++trabecular, androgens)
- \checkmark Carcinoid syndrome \rightarrow ~ 30% of patients (++insular)
- ✓ 23 cases of carcinoid heart disease reported in the literature



Clinical syndromes associated with ovarian neoplasms



Bari, 7-10 novembre 2013





Ovarian Carcinoid



Prognosis

- ✓ ~66% of cases: localized lesions (confined to ovary)
- ✓ 22-31% of cases: distant spread (evidence of metastases to other organs)
- ✓ prognosis favorable (~90% 5 years of survival rate with localized lesions)





Small cell (SC) NEC

- ✓ About 300 cases reported
- ✓ Hypercalcaemic type: undifferentiated carcinoma that is usually associated with <u>paraendocrine hypercalcaemia (2/3)</u> and is composed primarily of small cells.
- Pulmonary type: small cell carcinoma resembling pulmonary small cell carcinomas of neuroendocrine type

Large cell (LC) NEC

✓ Rare (35 cases) malignant tumour composed of large cells that show neuroendocrine differentiation.



Conclusions



- Two types of rare NET with diverse clinicopathological features and outcome are identified in the urinary system and genital organs: carcinoid tumour and neuroendocrine carcinoma (NEC). Both show the morphology and immunophenotype of NET originating in other organs
- The prognosis of carcinoid is favorabe in localized lesions, but metastases can be detected at the initial evaluation and they have been reported up to several years after removal, emphasizing the need for a long-term follow-up. NEC includes small cell carcinoma (SCC) and large cell NE carcinoma (LCNEC), the latter being exceedingly rare. Although the occurrence is very rare, it is highly aggressive.
- ✓ The endocrinologist must learn to recognize these tumors and to treat them as part of a multidisciplinary approach







Bari, 7-10 novembre 2013

RINGRAZIAMENTI al NET/RT-Team

Policlinico A. Gemelli

Roma

